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Background: PCAF is an important intrinsic histone acetyltransferases. This study tried to establish the effect of
PCAF on HCC cell apoptosis.
Method: Both in vitro and in vivo experiments including IHC, DAPI staining, caspase 3/7 activity assay, BrdU assay,
MTT assay, western immunoblotting and co-immunoprecipitation were used here.
Results: PCAF was found to be expressed at the low level in most of HCC cell lines. PCAF overexpression induced
cell apoptosis and growth arrest with increased Histone H4 acetylation and inactivation of AKT signaling in Huh7
and HepG2 cells. The opposite results were obtained by silencing PCAF in Hep3B cells. The co-immunoprecipitation
assay confirmed that PCAF protein was bound with histone H4 protein in the nucleus of Hep3B cells. Finally, the
in vivo experiment confirmed the findings mentioned-above.
Conclusion: These data identified PCAF promotes cell apoptosis and functions as a HCC repressor through
acetylating histone H4 and inactivating AKT signaling.
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Hepatocellular carcinoma (HCC) is currently the fifth most
common malignancy and the third most frequent cause of
cancer death worldwide [1]. The statistical data show that
HCC is the second most prevalent cause of cancer deaths
for male and the third for female in China [2]. Moreover,
the incidence of HCC in USA and west Europe countries
keeps rising each year [3]. Due to lack of the distinct clin-
ical manifestation and the aggressive feature of malignancy,
most of HCC patients are diagnosed at the advanced stage
and have no chance to receive the curative treatments like
liver transplantation and radical liver resection, which re-
sults in the unfortunate prognosis. Therefore, it is urgent
to figure out the pathogenesis of HCC and develop novel
tumor markers and target therapies.* Correspondence: raymondzhengxin@foxmail.com
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reproduction in any medium, provided the orP300/CBP-associated factor (PCAF), a well-known histone
acetyltransferases (HAT), was established in the research
about the oncogenic function of adenoviral E1A which
showed PCAF competed with E1A for binding to P300/CBP
and in turn repressed cellular transformation [4]. The same
investigation simultaneously demonstrated that PCAF had
the intrinsic HAT activity which was found to be attributed
to transcriptional activation [5]. Analysis of the sequence of
PCAF protein reveals that the C-terminal half of PCAF con-
tains the central HAT domain (within residues 725–819)
which is highly homologous to the yeast GCN5 (yGCN5)
[6]. Later, the functional experiment shows that the N-
terminal structure of PCAF, which is different with yGCN5,
is necessary for nucleosomal acetylation induced by the
HAT domain of PCAF [4]. In our previous studies, PCAF
was found to be frequently down-regulated in HCC tissues
compared to adjacent liver tissues as assessed by immuno-
histochemistry (IHC) staining and down-regulation of PCAFLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing survival after liver resection [7].
Among the various epigenetic regulatory mechanisms
that cause alteration of gene expression, histone acetyl-
ation has been considered as one of most significance [8].
The amino terminus of histones extends from the nucleo-
somal core and could be modified by acetyltransferases or
deacetylases. This modification leads to relaxation of chro-
matin structure facilitating transcriptional factors to bind
with relevant promoters of target gene sequences and conse-
quently controls numerous cell signal pathways {Shogren-
Knaak, 2006 #14} [9]. Through regulating lots of cell
pathways which control cell fate simultaneity, histone
acetylation has been found to contribute to inhibit the
growth and metastasis of gastrointestinal cancers includ-
ing gastric cancer, colorectal cancer and HCC [10,11].
Yamashita et al. found that down-regulating acetylation of
histone H4 by histone deacetylase inhibitor trichostatin A
(TSA) resulted in cell-cycle arrest and apoptosis of HCC
cells (HepG2 cells and Huh7 cells, respectively) [12]. The
results from other groups also confirmed the pro-
apoptotic effect of acetylation of histone H4 on HepG2
cells [13]. Interestingly, Lai and his colleagues found that
acetylated histone H4 inactivated AKT signaling and con-
sequently leaded to cell apoptosis in HCC [14]. Recently,
there are more evidences confirming inhibition of AKT
signaling is involved in increased cell apoptosis and growth
arrest induced by acetylating histone H4 in several cancers
including diffuse large B-cell lymphoma [15], non-small
cell lung cancer and ovarian cancer [16]. AKT is a well-
known serine/threonine kinase regulating its downstream
effectors that affect critical cellular processes. It has been
found that AKT signaling mediates cell apoptosis and
growth via distinct ways such as inactivating cell cycle in-
hibitors (p27 and p21) [17], inhibiting pro-apoptotic genes
(BAD and BIM), promoting cell cycle proteins (c-Myc,
cyclin D1) [18] and degrading the tumor suppressor pro-
tein p53 [19].
Here, we tried to address the following questions: 1.
Does PCAF affect cell apoptosis of HCC cells? 2. Are
AKT signaling and histone H4 involved in the pro-
apoptotic action of PCAF on HCC? 3. Does PCAF re-
press the growth of HCC xenografts?
Materials and methods
Materials
DMEM medium, RPMI 1640 medium, FBS and trypsin/
EDTA were from Invitrogen Co. (Carlsbad, CA, USA).
The PCAF expressing plasmid and its empty plasmid
pCMV6-Entry were both purchased from Origene Tech-
nologies Inc. (Rockville, MD, USA). PCAF siRNA se-
quences were obtained from Santa Cruz Biotechnology
(Catalog No.: sc-36198, Santa Cruz, CA, USA). The 18 s
rRNATaqMan probe (Hs99999901_s1) and PCAF TaqManprobe (Hs00187332_m1) were purchased from Applied
Biosystems (Carlsbad, CA, USA). The rabbit monoclonal
PCAF antibody, rabbit polyclonal phospho-AKT antibody
(which can be used to detect phosphorylated AKT1, AKT2
and AKT3), AKT antibody (which can be used to detect
total proteins of AKT1, AKT2 and AKT3), rabbit poly-
clonal acetyl-histone H4 (Lys16) antibody and rabbit poly-
clonal histone H4 antibody were from Cell Signaling
(Danvers, MA, USA). The mouse monoclonal β-actin anti-
body and 4,6-diamidino-2-phenylindole (DAPI) were from
Boster Biotechnology (Wuhan, China). The Caspase-Glo®
3/7 Assay kit and Apo-ONE® Homogeneous Caspase-3/7
Assay were from Promega (Madison, WI, USA). The ter-
minal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labeling assay (Tunel) kit (Catalog No.: KGA7025)
was from KeyGEN BioTECH (Nanjing, China). The IHC
detection kit (Catalog No.: SP-9001) was purchased from
ZSGB Bio. (Beijing, China).
Cell culture
HCC cell lines (Hep3B, HepG2, PLC/PRF5 and SK
Hep1) were obtained from the American Type Culture
Collection (Manassas, VA, USA) and Huh7 cell line was
a kind gift from Prof. Kefeng Dou (Department of
Hepatobiliary Surgery, Xijing Hospital, Fourth Military
Medical University). SK Hep1, Hep3B cells and PLC/
PRF5 were cultured in complete MEM medium with
10% FBS. Huh7 cells were grown in DMEM medium
with 10% FBS. HepG2 cells were cultured in RPMI 1640
medium with 10% FBS.
Establishment of PCAF stable transfectant clones
PCAF expressing plasmid was transfected into Huh7 cells
using FuGENE6 Transfection Reagent from Promega
(Madison, WI, USA) as PCAF-expressing Huh7 cells (Huh7
PCAF cells). The pCMV6-Entry plasmid was transfected
into Huh7 cells as the control cells (Huh7 Control cells).
Stable transfection for both Huh7 PCAF cells and Huh7
Control cells was obtained after 2-week selection with
Geneticin (G418) from Invitrogen (Carlsbad, CA, USA) at a
dose of 600 μg/mL.
RNAi transfections
siRNA sequences against PCAF (Catalog No.: sc-36198)
and the scramble siRNAs (Catalog No. sc-37007) were
both from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Hep3B cells were seeded at the concentration of
0.2 × 106 per well in six-well plates and grown for over-
night. Then tumor cells in each well were transfected with
100 nM siRNAs using Lipofectamine RNAi MAX Reagent
(Invitrogen, CA, USA) according to the manufacturer’s in-
structions. The cells were used for further experiments at
48 h after transfection.
Figure 1 The expression of PCAF in HCC cell lines. (A) The
mRNA of PCAF in 6 kinds of HCC cell lines was examined by qRT-
PCR; (B) The protein expression of PCAF in 6 kinds of HCC cell lines
was examined by Immunoblotting.
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chain reaction (qRT-PCR)
Total RNA was isolated from HCC cell lines using the
Rneasy kit from Qiagen Co. (Valencia, CA, USA). cDNA
synthesis was carried out using the High Capacity cDNA
Reverse Transcription Kit from Applied Biosystems
(Carlsbad, CA, USA) to transcribe 2 μg of total RNA.
qRT-PCR was performed using ABI TaqMan Gene Ex-
pression assays in an ABI 7300 system. PCAF expressing
plasmid was used to make the standard curve as the
standard sample and 18 s rRNA was regarded as internal
control. The mRNA level of PCAF was normalized to 18 s
rRNA mRNA level in the same sample.
Co-Immunoprecipitation assay and western
immunoblotting
Co-immunoprecipitation assay was carried to examine the
interaction between PCAF protein and histone H4 protein
in Huh7 PCAF cells. Then, total protein lysate was obtained
in immunoprecipitation buffer (50 mM Tris–HCl, pH 8.0,
150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 2 μg/ml
aprotinin, 1 μg/ml leupeptin, 1 mM PMSF, 1 mM sodium
vanadate and 10 mM sodium fluoride). Next, the lysate was
precleared with protein A/G-agarose beads. Total protein
in supernatants was qualified by BCA method. Total pro-
tein was diluted into 1 μg/μL with PBS and mixed with pri-
mary antibodies against PCAF and histone H4 or IgG. The
mixtures were shaken on rotating shaker at 4°C for over-
night. The supernatant was collected and proceeded to im-
munoblotting assay.
Briefly, 30 μg protein samples were separated by de-
naturing gel electrophoresis. After transferred to PVDF
membrane, blots were probed overnight with the pri-
mary antibodies respectively. After washed 3 times by
TBST, blots were then incubated with the relevant sec-
ondary antibodies conjugated with HRP, and signals
were visualized using the HyGLO HRP detection kit
from Denville (Metuchen, NJ, USA) [20]. β-actin was
measured as internal control.
Cell proliferation and cell viability assays
For the proliferation assay, HCC cells were seeded into 96-
well plates at 5000 cells per well for 24 hours and assessed
using the BrdU ELISA kit from Roche Co. (Indianapolis,
IN). The 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) assay was used to assess cell viability
at 24, 48, 72 and 96 hours.
Cell apoptosis detection
We performed three distinct assessments to get the convin-
cing results of cell apoptosis here. First of all, cell apoptosis
was measured by fluorescence microscopy to identify apop-
totic nuclear changes (chromatin condensation and nuclear
fragmentation) after staining cells with DAPI. Next, theCaspase 3/7 activity assay was conducted using the Apo-
ONEW Homogeneous Caspase-3/7 Assay kit as described in
our previous studies [21]. Finally, cell apoptosis was assessed
by flow cytometry assay. Populations of apoptosis cells were
determined by staining cells with annexin V–FITC and PI
labeling, according to the manufacturer’s recommendations
(Alexa FluorW 488 annexin V/Dead Cell Apoptosis Kit,
Invitrogen, CA, USA). FACS analysis was performed using a
FACSCalibur (Becton Dickinson, San Jose, CA).In vivo experiments
Two million Huh7 PCAF cells or Huh7 Control cells
suspended in 150 μL of Matrigel were inoculated subcuta-
neously into the flanks of 4 to 6 weeks old male nude mice.
Tumor sizes were measured with calipers every 5 days.
Mice were censored when the tumor volume reached
1000 mm3. All experimental protocols were approved by
the institutional animal care and use committee of our
hospital. The IHC staining assay was performed to detect
the protein expression of PCAF, acetyl-histone H4 and
phospho-AKT in the xenograft tissues. The cell apoptosis
Figure 2 Overexpression of PCAF induced cell apoptosis and repressed proliferation in Huh7 cells. (A) At the levels of both mRNA and
protein, PCAF expression is increased by PCAF expressing plasmid in Huh7 cells; (B) Forced expression of PCAF induced a significant increase in
apoptosis of Huh7 cells as assessed by staining with DAPI followed by fluorescence microscopy (P < 0.004); (C) The activity of the pro-apoptotic
caspase 3 and 7 also showed up-regulated after ectopic expression of PCAF (P = 0.002); (D) Flow cytometry assay showed that the percents of
early apoptosis cells and late apoptosis cells was increased 2–3 folds in Huh7 PCAF cells than in Huh7 Control cells(P = 0.002); (E) Cell proliferation
as measured by BrdU incorporation was inhibited by forced expression of PCAF(P = 0.002); (F) As assessed by MTT assays, forced expression of
PCAF was found to reduce viability of Huh7 cells at all four time points significantly.
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according to the manufacturer’s guidelines. The details of
IHC protocal have been described previously [22].Statistical analysis
All experiments were performed in triplicates, repeated
2–3 times. And all data are expressed as means and
Figure 3 (See legend on next page.)
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Figure 3 Knockdown of PCAF suppressed cell apoptosis and promoted proliferation in Hep3B cells. (A) The mRNA and protein
expression of PCAF is down-regulated by siRNA structure against PCAF in Hep3B cells; (B) DAPI staining assay showed that knockdown of PCAF
repressed cell apoptosis of Hep3B cells significantly (P = 0.002); (C) The activity of caspase 3/7 was decreased greatly by knockdown of PCAF in
Hep3B cells (P = 0.002); (D) The percents of both early apoptotic cells and late apoptotic cells of Hep3B PCAF siRNA cells was decreased by
around 50% as assessed by flow cytometry (P = 0.008); (E) Silencing PCAF was found to promote proliferation of Hep3B cells in BrdU
incorporation ELISA assay apparently; (F) MTT assay displayed that knockdown of PCAF facilitated cell growth of Hep3B cells significantly.
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were compared with the Mann–Whitney test or Student-t
test. A P value of < 0.05 was used for significance. All stat-
istical analysis was performed using PRISM 4 (Graphypad,
La Jolla, CA, USA).
Results
The PCAF expression in HCC cell lines
To investigate the level of PCAF in HCC cell lines and se-
lect the appropriate cell models for the further experiment,
we detected the mRNA and protein expression of PCAF in
Hep3B, HepG2, Huh7, PLC/PRF/5 and SKHep1 cells by
qRT-PCR and immunoblotting. As shown in Figure 1A,
Hep3B cell expressed the highest mRNA level of PCAF,
while the mRNA expression of PCAF in Huh7, HepG2 and
PLC/PRF/5 cells was relatively low. The results ofFigure 4 PCAF regulated acetylation of histone H4 and phosphorylat
PCAF was bound with histone H4 directly; (B) Forced expression of PCAF i
Huh7 and HepG2 cells, and knockdown of PCAF in Hep3B cells deacetylateimmunoblotting assay verified these findings (Figure 1B), as
well. Thereby, Huh7 cells were selected for PCAF
overexpression experiment here, while Hep3B cells were
used in PCAF knockdown experiment.
Forced expression of PCAF induced cell apoptosis and
growth arrest in HCC cells
To determine the effect of PCAF on the growth of HCC
cells, we established Huh7 clones which over-expressed
PCAF stably by the PCAF expressing plasmid. As assessed
by qRT-PCR and immunoblotting assay, the mRNA and
protein expression of PCAF in Huh7 PCAF cells was signifi-
cantly higher than in Huh7 Control cells (Figure 2A). The
percentage of DAPI staining cells was around 40% in Huh7
PCAF cells, which was apparently higher than 20% in Huh7
Control cells (Figure 2B). Forced expression of PCAF wasion of AKT in HCC. (A) Co-immunoprecipitation assays showed that
ncreased acetylation of histone H4 and AKT phosphorylation in both
d histone H4 and activated AKT signaling.
Figure 5 (See legend on next page.)
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Figure 5 Forced expression of PCAF inhibited the growth of HCC xenografts, up-regulated histone H4 acetylation, suppressed
phosphorylation of AKT, and accelerated cell apoptosis. (A) IHC experiments was performed to verify the positive expression of PCAF in the
xenografts from Huh7 PCAF cells (a) and the negative staining of PCAF in the xenografts from Huh7 Control cells (b). The PCAF staining was
located in cell nucleus primarily indicated by black arrow. There was more acetylated histone H4 expressing in the xenografts from Huh7 PCAF
cells (c) than the xenografts from Huh7 PCAF cells (d). The acetylated histone H4 was found mainly in cell nucleus (black arrow). The
phosphorylation of AKT protein was upregulated in the xenografts from Huh7 PCAF cells (e), compared to the xenografts from Huh7 Control
cells (f). The phospho-AKT expression was detected in both cell nucleus (black arrow) and cytoplasm (white arrow); (B) Xenografts from Huh7
PCAF cells grew significantly slower than xenografts from Huh7 Control cells; (C) There were more apoptotic cells in the xenograft tissues from
Huh7 PCAF cells (a) than the xenograft tissues from Huh7 Control cells (b).
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Huh7 cells (Figure 2C). Flow cytometry apoptosis assays
also showed that the percents of apoptosis cells including
both early apoptosis cells and late apoptosis cells were in-
creased 2–3 folds in Huh7 cells by PCAF overexpression,
as shown in Figure 2D. Consistently, forced expression of
PCAF suppressed cell proliferation of Huh7 cells. As
assessed by luminometer, BrdU incorporation in Huh7 cells
was decreased to about 50% after overexpression of PCAF
(Figure 2E). The MTT experiments showed that forced ex-
pression of PCAF reduced viability of Huh7 cells at all four
time points significantly, as shown in Figure 2F.
To verify the pro-apoptotic activity of PCAF on HCC
cells, we increased the expression of PCAF in another kind
of HCC cells with low level of PCAF - HepG2 cell, as
shown in Additional file 1: Figure S1 A. The percentage of
DAPI staining cells in HepG2 cells with high level of PCAF
(HepG2 PCAF) was significantly higher than one in HepG2
cells with low level of PCAF (HepG2 Control) (Additional
file 1: Figure S1 B). Consistently, the activity of caspase 3/7
of HepG2 cells was up-regulated after enforcing PCAF ex-
pression, as well (Additional file 1: Figure S1 C). These re-
sults demonstrated that PCAF promoted apoptosis of
HepG2 cells in vitro.Knockdown of PCAF repressed cell apoptosis and
accelerated proliferation in Hep3B cells
To further determine the effect of PCAF on the cell apop-
tosis and proliferation of HCC cells, we silenced PCAF ex-
pression in Hep3B cells. The results of both qRT-PCR and
immunoblotting assays showed that PCAF expression in
Hep3B cells was decreased successfully by siRNAs transfec-
tion (Figure 3A). The percents of DAPI staining cells in
Hep3B PCAF siRNA group was significantly lower than
those in Hep3B Scr siRNA group (Figure 3B). Caspase 3/7
activity of Hep3B cells was decreased by about 40% after
knockdown of PCAF (Figure 3C). Flow cytometry assay also
showed that the percent of apoptosis cells including both
early apoptosis cells and late apoptosis cells in Hep3B PCAF
siRNA group was decreased by around 50% (Figure 3D). On
the other hand, silencing PCAF was found to promote pro-
liferation of Hep3B cells apparently by BrdU incorporation
ELISA assay (Figure 3E). Correspondingly, the results ofMTT assay displayed that knockdown of PCAF facilitated
cell growth of Hep3B cells significantly, as well (Figure 3F).
PCAF acetylated histone H4 directly and inhibited AKT
signaling
To figure out the underlying mechanism by which PCAF
induces cell apoptosis and growth arrest in HCC cells, we
tested the effect of PCAF on nuclear acetylation of histone
H4 and activation of AKTsignaling. As shown in Figure 4A,
the co-immunoprecipitation measurement showed that
PCAF protein was bound with histone H4 protein directly
in Huh7 cells. And the further immunoblotting assay
(Figure 4B) found that the level of acetylated histone H4
protein in wild type Hep3B cells with more PCAF expres-
sion seemed to be higher than one in Huh7 cells. As
expected, Huh7 PCAF cells had higher level of acetylated
histone H4 protein than Huh7 Control cells. Consequently,
forced expression of PCAF attenuated the phosphorylation
of AKT in Huh7 cells. In contrary, knockdown of PCAF
reduced the level of acetylation of histone H4 protein in
Hep3B cells and increased the phosphorylation of AKT.
To confirm this signaling cascade further, we conducted
western immunoblotting assay in HepG2 cells and found
that ectopic expression of PCAF in HepG2 cells enhanced
acetylation of histon H4 protein and eliminated phosphor-
ylation of AKT protein (Figure 4B).
PCAF inhibited tumor growth in HCC xenograft model
Based on the above-mentioned evidences showing that
PCAF promotes cell apoptosis and growth arrest in vitro,
we hypothesized that PCAF may impact HCC tumorigen-
esis in vivo. To test this hypothesis, Huh7 PCAF cells and
Huh7 Control cells were inoculated subcutaneously into 22
nude mice. Tumor size was measured with calipers every
5 days.
As expected, subcutaneous xenografts were detectable in
both groups after about 20 days. When the tumor size
reached 1000 mm3, the mice were sacrificed and the xeno-
grafts were harvested. To verify the overexpression of PCAF
in the xenografts from Huh7 PCAF cells, immunohisto-
chemistry staining was carried out using the primary anti-
body against PCAF. As shown in Figure 5A, strong
expression of PCAF protein was observed in the xenografts
from Huh7 PCAF cells, while negative PCAF staining was
Figure 6 Working model for the anti-HCC effect of PCAF and
downstream pathway. PCAF promotes apoptosis and inhibits
growth of HCC through acetylating histone H4 and inactivating
AKT signaling.
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ate the signaling cascade found in in vitro experiments, we
detected the protein expression of acetyl-histone H4 and
phospho-AKT in the xenograft tissues. The results showed
that there were higher expression of acetyl-histone H4 and
lower phospho-AKT expression in the xenograft tissues
established from Huh7 PCAF cells (Figure 5A).
Xenografts expressing PCAF grew significantly slower
than xenografts from Huh7 Control cells (Figure 5B).
Additionally, the TUNEL assay revealed that there were
more apoptosis cells in the xenograft tissues from Huh7
PCAF cells (Figure 5C).
Discussion
Besides the classical genetic mutations (such as chromo-
somal deletion, chromosomal rearrangements and gene
amplifications) have been established to be involved in
hepatocarcinogenesis, recent biochemistry researchers have
identified that several epigenetic alterations affect thetranscription and/or expression of oncogenic proteins and
repressors which play important roles in development and
progression of HCC [23]. Among them, acetylation of his-
tones emerges as the major epigenetic alteration and con-
tributed fundamentally to transcriptional regulation [24,25]
via allowing interconversion between permissive and repres-
sive chromatin structures and domains.
The acetylation level of histones depends on the balance
between the activities of HATs and histone deacetylases
(HDACs) which are ability to add or remove acetyl groups
from the lysines of histones respectively. There are several
lines of studies showing that dysregulation of HDACs exists
in various cancers including HCC and is responsible for in-
appropriate transcriptional activation attributed to the pro-
gression of these cancers [26,27]. However, there is limited
investigation reported about the role of HATs on the patho-
genesis of HCC. As aforementioned, PCAF is known as a
kind of histone acetyltransferases (HAT), which modulates
concurrently multiple cell pathways via acetylating histones
and non-histone proteins. In our previous study, PCAF was
down-regulated frequently in HCC tissues compared to ad-
jacent liver tissues and associated positively with better sur-
vival after liver resection [7]. And it’s down-regulation in
HCC tissues was found to be significantly correlated with
tumor TNM staging and intrahepatic metastasis. It seems
that PCAF functions as a tumor repressor in HCC, which is
consistent with its anti-tumor effect in other cancers [28]. In
this study, we measured the expression of PCAF in 5 kinds
of HCC cell lines and found PCAF expression was relative
low in 4 kinds of HCC cells (HepG2, Huh7, PLC/PRF/5,
and SKHep1), which indicates that there is limited expres-
sion of PCAF in most of HCC cell lines and is consistent
with our previous results.
PCAF has been found to acetylate histone H4 at lysine 8
[29]. Strikingly, Lai et al. have verified that acetylation of his-
tone H4 induces cell apoptosis and growth arrest via
inhibiting AKT signaling [14]. Hence, we tested here the ac-
tion of PCAF on apoptosis and growth of HCC cells by dif-
ferent ways and found that forced expression of PCAF
promoted cell apoptosis and suppressed proliferation of
HCC cells. In contrary, knockdown of PCAF repressed cell
apoptosis and accelerated HCC cell proliferation. These re-
sults supported strongly that PCAF has the anti-HCC
function via inducing cell apoptosis and inhibiting cell
proliferation. To further figure out the underlying molecu-
lar mechanism, we examined the regulatory function of
PCAF on AKT signaling. Several studies have shown that
AKT signaling is aberrantly hyperactivated in HCC by dis-
tinct ways including down-regulation of PIK3IP1 (phos-
phatidylinositol-3-kinase interacting protein I) [13] and
overexpression of COX2 [30]. AKT signaling has been con-
sidered to contribute to inhibit cell apoptosis and facilitate
cell proliferation. In this study, we found that overexpression
of PCAF increased the acetylation level of histone H4
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The opposite results were obtained after silencing PCAF in
HCC cells. As shown in Figure 6, these data demonstrate
that PCAF could play its anti-HCC action through acetylat-
ing histone H4 and in turn inactivating AKT signaling,
which is also consistent with the conclusion from Lai group
that acetylation of histone H4 inhibits AKT signaling and
promotes apoptosis in HCC.
In the previous article [31], PCAF was found to induce
cell cycle arrest in a P53-dependent manner. In this
study, wild type Hep3B cell is a kind of P53-null cell
[32] and Huh7 cells [33] expresses mutant p53. There-
fore, the pro-apoptotic function of PCAF on these two
kinds of cell lines found in this investigation is specu-
lated to be in a p53-independent manner. However,
PCAF was also confirmed to rescue DNA-binding and
growth-suppressive activity of mutant forms of p53 in
various cancers [34]. This mechanism could be involved
in the pro-apoptotic action of PCAF in Huh7 cells,
which needs be investigated more. Finally, we performed
the HCC xenograft experiments and showed that xeno-
graft with high PCAF expression grew slower than one
with low PCAF expression significantly, which further
proves the anti-HCC effect of PCAF. In addition, the
IHC assay in the xenograft tissues verified in vivo that
PCAF increased acetylation of histone H4 and repressed
AKT phosphorylation in HCC cells. The pro-apoptotic
effect of PCAF in HCC cells was finally established by
TUNEL assay in xenograft tissues.
Conclusions
In summary, this study shows that PCAF is expressed at
the low level in most of HCC cell lines and represses the
HCC growth via inducing apoptosis and promoting pro-
liferation. Furthermore, we figure out that PCAF, as a
kind of HATs, acetylates histone H4 and inactivates
AKT signaling, which could be the underlying molecular
mechanism of the pro-apoptotic function of PCAF in
HCC. It is well-known that acetylation of histones plays
an important role in the pathogenesis of HCC and is de-
termined by the equilibrium between the activities of
HATs and HDACs. While some studies have revealed
the role of HDACs in HCC, there is limited literature
addressing the effect of HATs on the progression of
HCC. This study reveals the anti-HCC function of PCAF
first and supplies with a new sight to the epigenetic
regulation of HCC. PCAF could potentially serve as a
clinical biomarker and therapy target for HCC.
Additional file
Additional file 1: Figure S1. (A) The expression of PCAF in HepG2 cells
was increased significantly by PCAF expressing plasmid at the level of
both mRNA and protein; (B) The percentage of apoptotic cells wasincreased by more than two-fold after forced expression of PCAF in
HepG2 cells; (C) The caspase3/7 activity of HepG2 cells was enhanced
dramatically after ectopic expression of PCAF.
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